Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.

New Brunswick-based Johnson & Johnson and Bedminster-based Intra-Cellular Therapies, Inc. have entered into a definitive agreement ...

Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

Compulsive spending can be a symptom in the manic phase of bipolar disorder. Read more to find out what triggers this ...

People with bipolar disorder often experience a higher rate of manic episodes during the spring season. Changes in religious ...

Religious Issues A common occurrence in the manic phase of bipolar disorder is intensifying or changing religious beliefs. For example, Bill changed between Christian, Buddhist, Taoist ...

In the past, we have had great difficulty stopping sufferers from lapsing back into the manic or depressive phase of the illness,' says Dr John Cookson, a consultant psychiatrist at the Royal ...

JNJ-18038683 is under clinical development by Johnson & Johnson and currently in Phase II for Bipolar Disorder (Manic Depression). According to GlobalData, Phase II drugs for Bipolar Disorder (Manic ...

for the acute treatment of manic or mixed episodes in adults with bipolar I disorder. Previously approved in 2009 for schizophrenia, iloperidone demonstrated significant efficacy in a phase 3 ...

Lupus can sometimes mimic bipolar disorder, especially when neuropsychiatric symptoms like mood changes, mania, or psychosis are involved. These symptoms may stem from neuropsychiatric lupus ...